Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies.
The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH appeared first on MedCity News.
Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed the cruise ship hantavirus outbreak on PBS NewsHour, Fox’s LiveNow From Fox, and CBS News’ CBS
